Compare AbbVie Inc (ABBV) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Box Inc — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Box Inc trades at $28.94 (market cap $4.00B). The key difference: AbbVie Inc is far larger — about 112.5× Box Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Box Inc pays none. Which is the better fit depends on your goals.
| ABBV | BOX | |
|---|---|---|
Market Cap | $449.91B | $4.00B |
Sector | Health | Technology |
52-Week High | $261.07 | $33.73 |
52-Week Low | $184.85 | $21.37 |
Enterprise Value | $513.38B | $4.55B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
BOX trades at $28.85, up 3.44% today, with a bullish technical signal from moving averages and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income surging to $244.62M, though Q2 2026 EPS is expected at $0.4. The company expanded Box Zones to new regions, enhancing global data governance capabilities.
The outlook is positive with a $37 consensus price target, but risks include high P/E of 44.3 and overbought RSI levels. Earnings growth and strategic expansions present opportunities, yet investor caution is warranted near-term due to valuation and potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
